What it's for (Indications)
- Enoxacin, a synthetic broad-spectrum fluoroquinolone antibiotic, is primarily indicated for the treatment of various bacterial infections caused by susceptible microorganisms.
- Historically, its main applications included uncomplicated and complicated urinary tract infections (UTIs), including pyelonephritis and cystitis, and certain respiratory tract infections.
- It demonstrated efficacy against a range of Gram-negative bacteria such as *Escherichia coli*, *Klebsiella pneumoniae*, *Proteus mirabilis*, and *Pseudomonas aeruginosa*, as well as some Gram-positive bacteria like *Staphylococcus aureus*.
- However, its use has become less common in current clinical practice due to the development of newer fluoroquinolones with improved efficacy and safety profiles, alongside increasing antimicrobial resistance patterns observed globally.
- Prescribers should consult current local antibiograms, clinical guidelines, and susceptibility testing results to ascertain its appropriate place in therapy, if any, for specific infections and patient populations.
- Given the potential for serious adverse effects associated with fluoroquinolones, its use is generally reserved for situations where other, less toxic agents are ineffective or contraindicated.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of enoxacin (e.g., Enoxabid) must be meticulously individualized based on the severity and type of infection, the susceptibility of the causative pathogen determined by culture and sensitivity testing, and importantly, the patient's renal function. For adult patients with normal renal function, typical oral dosages for uncomplicated urinary tract infections generally range from 200 mg to 400 mg administered twice daily (every 12 hours) for a duration typically ranging from 3 to 10 days, depending on the specific pathogen, clinical response, and established treatment guidelines. For more complicated infections, higher doses or longer treatment durations may be required, but a maximum daily dose should not be exceeded. Renal dose adjustment is critically important in patients with impaired kidney function to prevent drug accumulation and potential toxicity. Specific guidelines based on creatinine clearance values must be meticulously followed, often involving a reduction in total daily dose or an extension of the dosing interval. Due to concerns regarding potential cartilage damage in developing joints, pediatric use of enoxacin is generally contraindicated and should be avoided. |
Safety & Warnings
Common Side Effects
- Like other fluoroquinolone antibiotics, enoxacin is associated with a comprehensive range of potential adverse effects, which can vary significantly in incidence and severity.
- Common side effects frequently involve the gastrointestinal system, manifesting as nausea, vomiting, diarrhea, abdominal pain, and dyspepsia.
- Central nervous system (CNS) effects are also common and include headache, dizziness, insomnia, and confusion.
- Less common but more serious adverse events include a significant risk of tendinitis and tendon rupture (particularly affecting the Achilles tendon), peripheral neuropathy (which can be irreversible), and more severe central nervous system disturbances such as seizures, psychosis, hallucinations, and intracranial hypertension.
- Other important potential side effects encompass cardiac abnormalities like QTc prolongation and the risk of Torsades de Pointes, dysglycemia (both hypoglycemia and hyperglycemia), hepatotoxicity, severe hypersensitivity reactions (e.
- g.
- , anaphylaxis, Stevens-Johnson syndrome), and phototoxicity requiring avoidance of excessive sun exposure.
- Patients should be explicitly advised to seek immediate medical attention if experiencing severe pain or swelling in tendons, unusual numbness, tingling, or weakness in extremities, or any signs of an allergic reaction.
Serious Warnings
- Black Box Warning: Fluoroquinolones, including enoxacin, are associated with serious adverse reactions that may be irreversible and occur together. These include disabling and potentially irreversible serious adverse reactions that have occurred in patients who received fluoroquinolones, including tendinitis and tendon rupture, peripheral neuropathy, and central nervous system effects. Discontinue enoxacin immediately and avoid the use of systemic fluoroquinolones in patients experiencing any of these serious adverse reactions. Tendinitis and tendon rupture can occur at any age but the risk is increased in older patients (typically over 60 years of age), those also taking corticosteroids, and patients with kidney, heart, or lung transplants. Peripheral neuropathy, which may be irreversible, can occur rapidly after starting the drug. Central nervous system effects include seizures, increased intracranial pressure (pseudotumor cerebri), and toxic psychoses. Enoxacin should be avoided in patients with a known history of myasthenia gravis exacerbation, as it may worsen muscle weakness. The serious risks associated with fluoroquinolones generally outweigh the benefits for patients with acute bacterial sinusitis (ABS), acute exacerbation of chronic bronchitis (AECB), and uncomplicated urinary tract infections (uUTI) who have other treatment options. For these conditions, enoxacin should be reserved for use in patients who have no alternative treatment options.
- Enoxacin, as a representative of the fluoroquinolone class, carries significant and serious warnings due to its potential for severe and potentially disabling adverse reactions, necessitating a careful assessment of its benefits versus risks for each patient.
- A prominent Black Box Warning applies to all systemic fluoroquinolones, including enoxacin, concerning the increased risk of disabling and potentially irreversible serious adverse reactions that can occur together, including tendinitis and tendon rupture, peripheral neuropathy, and central nervous system effects (e.
- g.
- , seizures, psychoses, depression, suicidal thoughts).
- These reactions can occur at any age and typically manifest within hours to weeks after initiation of the drug.
- Patients experiencing symptoms suggestive of tendinitis (pain, swelling, inflammation, or rupture of a tendon), peripheral neuropathy (pain, burning, tingling, numbness, or weakness), or significant CNS effects should discontinue the drug immediately and contact their physician.
- Other critical warnings include QTc prolongation and the risk of Torsades de Pointes, particularly in patients with pre-existing cardiac conditions, uncorrected hypokalemia or hypomagnesemia, or those on concurrent medications known to prolong the QT interval.
- Enoxacin can also exacerbate muscle weakness in patients with myasthenia gravis, lead to severe hypoglycemia or hyperglycemia, and precipitate *Clostridium difficile*-associated diarrhea (CDAD).
- Use in pediatric patients and pregnant/lactating women is generally contraindicated due to the risk of cartilage damage in weight-bearing joints and other developmental concerns.
- Photosensitivity reactions are also a concern, advising patients to avoid excessive sun exposure and use protective clothing/sunscreen.
- Renal impairment necessitates dosage adjustment to prevent drug accumulation and toxicity.
How it Works (Mechanism of Action)
Enoxacin exerts its potent bactericidal effect by targeting essential bacterial enzymes involved in DNA replication and integrity. As a member of the fluoroquinolone class of antibiotics, its primary mechanism of action involves the selective inhibition of bacterial DNA gyrase (also known as topoisomerase II) and topoisomerase IV. DNA gyrase is a crucial enzyme primarily found in Gram-negative bacteria, responsible for introducing negative supercoils into bacterial DNA, a process absolutely necessary for DNA replication, transcription, and repair. Topoisomerase IV, more prominently targeted in Gram-positive bacteria, is involved in the decatenation of replicated DNA chromosomes, a vital step in bacterial cell division. By binding to and inhibiting these bacterial topoisomerase enzymes, enoxacin prevents bacterial DNA synthesis and eventually leads to the fragmentation of the bacterial chromosome, resulting in irreparable damage and subsequent bacterial cell death. This interference with fundamental bacterial processes confers its broad-spectrum antibacterial activity, although resistance mechanisms can develop over time.
Commercial Brands (Alternatives)
No other brands found for this formula.